Featured Research

from universities, journals, and other organizations

Call to tighten up value for money appraisals of new drugs in England

Date:
December 14, 2013
Source:
BMJ-British Medical Journal
Summary:
The body that appraises the clinical and cost effectiveness of new drugs in England would do well to take a leaf out of its sister organizations' books in Wales and Scotland, says an editorial in the Drug and Therapeutics Bulletin.

The body that appraises the clinical and cost effectiveness of new drugs in England would do well to take a leaf out of its sister organizations' books in Wales and Scotland, says an editorial in the Drug and Therapeutics Bulletin (DTB).

Related Articles


Between 30% and 40% of all new drug appraisals in the three countries have to be jettisoned, because the manufacturer in question has failed to supply the evidence needed to make the case for the drug, says DTB.

But unlike Scotland and Wales, where this situation usually prompts a recommendation for the drug to be rejected for use in the NHS, this is not the case in England, where such decisions are usually left up to the discretion of the local decision-making bodies.

This leads to "the inevitable duplication of effort and the potential for postcode availability," it says.

"We believe that England should follow the example of Scotland and Wales and not support use of a medicine when the company does not comply with the submission process," it contends.

While the appraisal processes in Scotland and Wales cover most new drugs and licensed indications for treatment, this responsibility largely falls to local commissioning groups in England.

DTB therefore also suggests that it might be more efficient and economical if just one UK body was responsible for evaluating the clinical and cost effectiveness of new drugs, given that all three bodies will be reviewing the same data.

"It could be argued that in a time of financial austerity, it might be more economical to run a single UK appraisal service to supply the same information to each appraisal committee (national or local)," it says.

Twenty years ago the NHS general practice drug bill came to 2.6 billion a year. Now those same costs have quadrupled to more than 10 billion a year.

During this time, the systems for evaluating the financial and clinical benefits of drugs has vastly improved across the UK, with the creation of three authoritative bodies in England, Wales, and Scotland, says DTB.

But these organizations shouldn't be resting on their laurels, just yet, it says.


Story Source:

The above story is based on materials provided by BMJ-British Medical Journal. Note: Materials may be edited for content and length.


Cite This Page:

BMJ-British Medical Journal. "Call to tighten up value for money appraisals of new drugs in England." ScienceDaily. ScienceDaily, 14 December 2013. <www.sciencedaily.com/releases/2013/12/131214144852.htm>.
BMJ-British Medical Journal. (2013, December 14). Call to tighten up value for money appraisals of new drugs in England. ScienceDaily. Retrieved March 2, 2015 from www.sciencedaily.com/releases/2013/12/131214144852.htm
BMJ-British Medical Journal. "Call to tighten up value for money appraisals of new drugs in England." ScienceDaily. www.sciencedaily.com/releases/2013/12/131214144852.htm (accessed March 2, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, March 2, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Treadmill Test Can Predict Chance Of Death Within A Decade

Treadmill Test Can Predict Chance Of Death Within A Decade

Newsy (Mar. 2, 2015) Johns Hopkins researchers analyzed 58,000 heart stress tests to come up with a formula that predicts a person&apos;s chances of dying in the next decade. Video provided by Newsy
Powered by NewsLook.com
GlaxoSmithKline and Novartis Try Swapping Success

GlaxoSmithKline and Novartis Try Swapping Success

Reuters - Business Video Online (Mar. 2, 2015) GlaxoSmithKline and Novartis have completed a series of asset swaps worth more than $20 billion. As Grace Pascoe reports they say the deal will reshape both drugmakers. Video provided by Reuters
Powered by NewsLook.com
How Can West Africa Rebuild After Ebola?

How Can West Africa Rebuild After Ebola?

Reuters - Business Video Online (Mar. 2, 2015) How best to rebuild the three West African countries struggling with Ebola will be discussed in Brussels this week. As Hayley Platt reports Sierra Leone has the toughest job ahead - its once thriving economy has been ravaged by the disease. Video provided by Reuters
Powered by NewsLook.com
Doctors Often Give In To Vaccine-Wary Parents

Doctors Often Give In To Vaccine-Wary Parents

Newsy (Mar. 2, 2015) A new survey published in the journal Pediatrics found many doctors are giving in to parents&apos; requests to delay vaccinating their children. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins